in registered deaths resulting from the given meteorological conditions compared with the average meteorological conditions.
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Cav-1 Regulates EphB4-Mediated Arteriovenous Fistula Maturation
Toshihiko Isaji, Takuya Hashimoto, Bogdan Yatsula, Haidi Hu, Tun Wang, Xiangjiang Guo, Alan Dardik. Yale University School of Medicine, New Haven, Conn
Objectives: Arteriovenous fistula (AVF) continues to be the most common access created for hemodialysis. However, many AVFs fail to mature, suggesting a need to improve AVF maturation. Caveolin1 (Cav-1) is the major scaffolding protein of caveolae, a distinct microdomain that serves as a flow-activated mechanosensor at the membrane of endothelial cells; Eph-B4 is the embryonic venous determinant. We have previously shown that Cav-1 is a mechanism of Eph-B4-mediated vessel remodeling in the murine vein graft model. We have also shown that Eph-B4 expression increases during AVF maturation and Eph-B4 activity inhibits venous remodeling in the murine AVF model. Then we hypothesized that Cav-1 is a critical regulator of Eph-B4-mediated AVF maturation through inhibition of eNOS activity.
Methods: We used a mouse aortocaval fistula model. The venous AVF limb and control (sham) inferior vena cava (IVC) of wild-type C57BL/6 (WT) were compared for Cav-1 expression. AVFs of WT mice, Cav-1 knockout (KO) mice, Cav-1 endothelial reconstituted (RC) mice, and Eph-B4 heterozygous (Eph-B4 het) mice were analyzed. A Cav-1 scaffolding domain peptide (cavtratin) was administrated to stimulate Cav-1 signaling; ephrinB2/Fc was used to stimulate Eph-B4 signaling. Vessel remodeling was assessed postoperatively by serial ultrasound measurements of the IVC/AVF diameter. AVFs were harvested at day 21 and examined with histology; IVC wall thickness was measured by computerized morphometry.
Results: Both Cav-1 mRNA and protein were increased in the fistula veins compared with control veins. Cav-1 KO mice showed enhanced venous remodeling with increased eNOS activity compared with WT mice. Inhibition of remodeling by ephrin-B2/Fc in WT mice was abolished in Cav-1 KO mice, but maintained in Cav-1 RC mice (Fig A) . Administration of cavtratin decreased the fistula wall thickness in WT mice as well as in Eph-B4 het mice (Fig B) .
Conclusions: Endothelial Cav-1 is a critical regulator of Eph-B4-mediated AVF maturation. Manipulation of Cav-1 function may improve arteriovenous maturation within the fistula environment.
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The Effect of Ischemia on Adipose-Derived Mesenchymal Stem Cells Expression In Vivo Tariq Almerey, Ruba Sheikh-ali, Houssam Farres, Albert G. Hakaim. Mayo Clinic, Jacksonville, Fla
Objectives: Several animal models have demonstrated improvement in mesenchymal stem cells (MSCs) count and paracrine secretions under hypoxic conditions. We have demonstrated an increase in adipose derived mesenchymal stem cells (ADMSCs) count in ischemic compared with nonischemic tissues in a previous in vivo study. This follow-up study was performed to investigate the effect of critical limb ischemia, in a human model, on in-situ ADMSCs paracrine effects.
Methods: Nine patients with end-stage lower extremity ischemia requiring amputation were prospectively identified. The average age was 73 years and 55.5% were males. All patients had an American Society of Anesthesiologists score of 3 or higher. After patients consent was obtained, samples were taken from the amputated lower extremities (distal) and healthy amputation stumps (proximal). Samples of adipose and arterial tissues were obtained from the ischemic part (distal) and nonischemic part (proximal). After tissue processing, the cDNA was then used in reverse transcriptase polymerase chain reaction using Bio-Rads Prime PCR Probe Assays and IL-6, NOSTRIN, PROM1 and VEGFA gene expression were measured. Results: A paired t test was run for each set of data to determine whether the difference in expression levels between nonischemic (proximal) and ischemic tissues (distal) were significantly different (Fig) . None of the comparisons was statistically significant. However, arterial VEGFA expression was higher in the ischemic compared with nonischemic tissues and seemed to be trending toward significance with a P value of .1. On the other hand, IL6 expression was higher in the nonischemic compared with ischemic tissues (P ¼ .2).
Conclusions: This study showed an increase in the VEGFA expression by the arterial MSCs in ischemic tissues which might indicate an attempt of the arterial MSCs to stimulate angiogenesis and vasculogenesis in the setting of ongoing ischemia. However, a larger sample size is needed to reach statistical significance. Methods: This multicenter retrospective cohort study included patients with at least one anatomic IFU violation for EVAR undergoing either elective EVAR or elective OR for AAA. Demographics, anatomic data, and follow-up data were collected on patients from 3 academic centers from 2003 to 2016. Device specific IFU was used for EVAR patients whereas a generic IFU for EVAR was applied to the OR patients. The main outcome of interest was overall survival. Kaplan-Meier survival and Cox proportional hazards modeling were performed. Inverse propensity score weights were used to adjust for differences in treatment selection.
Results: The study population included 202 EVAR patients and 224 OR patients with at least one anatomic IFU violation for EVAR. OR patients were more likely to be younger (70.8 years old vs 78.1 years old) and more hypertensive (80% vs 69%) compared with EVAR patients. OR patients were more likely to have proximal aortic neck IFU violations (75% vs 47%) and were less likely to have iliac IFU violations (65% vs 79%). Median follow-up was 5.4 .3] and 5.2 [IQR 3.5-7.2] years for OR and EVAR patients, respectively. All-cause mortality was 30.0%. Kaplan-Meier survival analysis revealed a significant association between patients undergoing OR and increased long term survival (log-rank P < .0001; Fig) . When adjusted for possible confounders and weighted for propensity for treatment through Cox hazard modelling, the association remained significant, (HR, 0.6 [95% CI, 0.4-0.9]). Subgroup survival analysis for proximal neck IFU violation showed no difference in mortality between OR and EVAR (HR, 1.3 [95% CI, 0.6-2.7]).
Conclusions: When adjusted for important clinical variables and propensity to undergo EVAR vs OR, our study identified that patients with IFU violations have improved overall long term survival with open treatment. When evaluating AAA patients with anatomic IFU violations, caution should be applied when considering EVAR.
Author Disclosures: P. Charbonneau: Nothing to disclose; L. Dubois: Nothing to disclose; H. L. Gill: Nothing to disclose; M. Habib: Nothing to disclose; C. Herman: Nothing to disclose; K. Hongku: Nothing to disclose; S. Hossain: Nothing to disclose; O. Steinmetz: Nothing to disclose.
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Long-Term Advantage of Iliac Branch Devices over Flared Limbs in the Treatment of Common Iliac Aneurysms
Rodolfo Pini, GianLuca Faggioli, Giuseppe Indelicato, Enrico Gallitto, Chiara Mascoli, Gargiulo Mauro, Andrea Stella. University of Bologna, Bologna, Italy
Objectives: The endovascular treatment (EVAR) of abdominal aortic aneurysms (AAA) is often associated with the treatment of common iliac artery dilatation (CID). The treatment options for CID can be either flared limbs (FL) or iliac branch devices (IBD) in selected cases but their efficacy is still matter of debate. Aim of the present study was to evaluate the perioperative and long-term outcome of EVAR with FL or IBD for CID.
Methods: From 2012 to 2017, patients treated with standard EVAR and FL with aorto-iliac anatomy fit for the implantation of IBD were retrospectively selected and compared with patients treated with standard EVAR and IBD. Iliac complications (IC) in terms of hypogastric loss, limb thrombosis, type 1b or type 3 endoleak (T1bEL, T3EL) were considered at 30-day and in the follow-up. Follow-up was performed by duplex evaluation at 3, 6, and 12 months and yearly thereafter. Comparison of the perioperative and long-term outcomes were performed by c 2 , life-table, and KaplanMeyer analyses.
Results: One-hundred twelve patients were included in the study for a total 162 iliac treatment examined: 105 (65%) with FL and 57 (35%) with IBD. In patients treated with IBD, Gore or Cook device were implanted in 26% and 74% of cases, otherwise for FL devices Anaconda, Gore, Medtronic, or Cook in 24%, 21%, 19% and 36%, respectively were used. Evaluating preoperative anatomic characteristic the IBD group had a significant higher CID diameter compared with FL (33 6 12 mm vs 22 6 2 mm); the other preoperative anatomic characteristics were similar. The procedural time and the volume of contrast medium were significantly higher for IBD compared with FL procedure (90 6 33 minutes vs 70 6 25 minutes; P ¼ .01; 130 6 40 mL vs 80 6 20 mL; P ¼ .01, respectively). The perioperative rate of IC were similar between IBD and FL (0% vs 3.8% [hypogastric loss]; P ¼ .25). At a mean follow-up of 31 6 8 months there were 10 IC, all in the FL group (4 hypogastric loss, 4 T1bEL and 2 limb occlusion). By life-table and Kaplan-Meyer analysis the IC-free survival was significantly higher in the IBD group after 4 years of follow-up (1-year 100% vs 96%; P ¼ .36; 2-year 100% vs 94%; P ¼ .14; 3-year 100% vs 91%; P ¼ .07; 4-year 100% vs 87%; P ¼ .03; 5-year 100% vs 78% P ¼ .02). 
